Papers associated with central nervous system (and kcnh2)

Limit to papers also referencing gene:
Show all central nervous system papers

???pagination.result.count???

???pagination.result.page??? ???pagination.result.prev??? 1 2

Sort Newest To Oldest

Sort Oldest To Newest

	Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine., Sánchez-Chapula JA., Naunyn Schmiedebergs Arch Pharmacol. December 1, 2004; 370 (6): 484-91.
	Activation of cardiac human ether-a-go-go related gene potassium currents is regulated by alpha(1A)-adrenoceptors., Thomas D., J Mol Med (Berl). December 1, 2004; 82 (12): 826-37.
	Identification and characterisation of a novel KCNQ1 mutation in a family with Romano-Ward syndrome., Zehelein J., Biochim Biophys Acta. November 5, 2004; 1690 (3): 185-92.
	The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping., Witchel HJ., Mol Pharmacol. November 1, 2004; 66 (5): 1201-12.
	Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels., Gögelein H., Naunyn Schmiedebergs Arch Pharmacol. September 1, 2004; 370 (3): 183-92.
	Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone., Zitron E., Naunyn Schmiedebergs Arch Pharmacol. August 1, 2004; 370 (2): 146-56.
	Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects., Schram G., Br J Pharmacol. August 1, 2004; 142 (8): 1300-8.
	Structural determinants of HERG channel block by clofilium and ibutilide., Perry M., Mol Pharmacol. August 1, 2004; 66 (2): 240-9.
	Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG., Hayashi K., Clin Sci (Lond). August 1, 2004; 107 (2): 175-82.
	Molecular basis of slow activation of the human ether-a-go-go related gene potassium channel., Subbiah RN., J Physiol. July 15, 2004; 558 (Pt 2): 417-31.
	Activation properties of Kv4.3 channels: time, voltage and [K+]o dependence., Wang S., J Physiol. June 15, 2004; 557 (Pt 3): 705-17.
	Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action., Thomas D., Br J Pharmacol. June 1, 2004; 142 (3): 485-94.
	Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels., Yang BF., Acta Pharmacol Sin. May 1, 2004; 25 (5): 554-60.
	Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels., Dong DL., Basic Clin Pharmacol Toxicol. May 1, 2004; 94 (5): 209-12.
	Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin., Thomas D., Naunyn Schmiedebergs Arch Pharmacol. May 1, 2004; 369 (5): 462-72.
	Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine., Lee SY., J Cardiovasc Pharmacol. May 1, 2004; 43 (5): 706-14.
	BmTx3, a scorpion toxin with two putative functional faces separately active on A-type K+ and HERG currents., Huys I., Biochem J. March 15, 2004; 378 (Pt 3): 745-52.
	Differential recovery of action potential duration and HERG currents from the effects of two methanesulfonamide class III antiarrhythmic agents, KCB-328 and dofetilide., Lee K., J Cardiovasc Pharmacol. November 1, 2003; 42 (5): 648-55.
	Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine., Scholz EP., Naunyn Schmiedebergs Arch Pharmacol. November 1, 2003; 368 (5): 404-14.
	Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels., Thomas D., Br J Pharmacol. November 1, 2003; 140 (5): 996-1002.
	Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen., Thomas D., Naunyn Schmiedebergs Arch Pharmacol. July 1, 2003; 368 (1): 41-8.
	[Electropharmacological assessment of the risk of drug-induced long-QT syndrome using native cardiac cells and cultured cells expressing HERG channels]., Nakaya H., Nihon Yakurigaku Zasshi. June 1, 2003; 121 (6): 384-92.
	The antipsychotic drug chlorpromazine inhibits HERG potassium channels., Thomas D., Br J Pharmacol. June 1, 2003; 139 (3): 567-74.
	Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes., Liu J., J Gen Physiol. June 1, 2003; 121 (6): 599-614.
	Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain., Sănchez-Chapula JA., Mol Pharmacol. May 1, 2003; 63 (5): 1051-8.
	RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies., Anantharam A., J Biol Chem. April 4, 2003; 278 (14): 11739-45.
	Drug- and mutagenesis-induced changes in the selectivity filter of a cardiac two-pore background K+ channel., Hajdú P., Cardiovasc Res. April 1, 2003; 58 (1): 46-54.
	Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency., Ishii K., Cardiovasc Res. March 1, 2003; 57 (3): 651-9.
	Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5., Peukert S., J Med Chem. February 13, 2003; 46 (4): 486-98.
	C-terminal domains implicated in the functional surface expression of potassium channels., Jenke M., EMBO J. February 3, 2003; 22 (3): 395-403.
	Interaction between tetraethylammonium and permeant cations at the inactivation gate of the HERG potassium channel., Shimizu H., Jpn J Physiol. February 1, 2003; 53 (1): 25-34.
	Relevance of the proximal domain in the amino-terminus of HERG channels for regulation by a phospholipase C-coupled hormone receptor., Gómez-Varela D., FEBS Lett. January 30, 2003; 535 (1-3): 125-30.
	Functionally-distinct proton-binding in HERG suggests the presence of two binding sites., Bett GC., Cell Biochem Biophys. January 1, 2003; 39 (3): 183-93.
	Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241., Gessner G., Br J Pharmacol. January 1, 2003; 138 (1): 161-71.
	Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action., Kushida S., Eur J Pharmacol. December 13, 2002; 457 (1): 19-27.
	The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia., Scherer CR., Br J Pharmacol. November 1, 2002; 137 (6): 892-900.
	Structural and functional role of the extracellular s5-p linker in the HERG potassium channel., Liu J., J Gen Physiol. November 1, 2002; 120 (5): 723-37.
	Histidines 578 and 587 in the S5-S6 linker of the human Ether-a-gogo Related Gene-1 K+ channels confer sensitivity to reactive oxygen species., Pannaccione A., J Biol Chem. March 15, 2002; 277 (11): 8912-9.
	The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels., Thomas D., J Pharmacol Exp Ther. February 1, 2002; 300 (2): 543-8.
	[Cardiotoxicity of lindane, a gamma isomer of hexachlorocyclohexane]., Sauviat MP., J Soc Biol. January 1, 2002; 196 (4): 339-48.
	Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes., Bachmann A., Naunyn Schmiedebergs Arch Pharmacol. November 1, 2001; 364 (5): 472-8.
	Effects of gallium and mercury ions on transport systems., Moschèn., J Dent Res. August 1, 2001; 80 (8): 1753-7.
	Molecular cloning and expression of cERG, the ether à go-go-related gene from canine myocardium., Zehelein J., Pflugers Arch. May 1, 2001; 442 (2): 188-91.
	Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 2nd communication: lack of central nervous system and cardiovascular effects., Kreutner W., Arzneimittelforschung. May 1, 2000; 50 (5): 441-8.
	Functional analysis of a mouse brain Elk-type K+ channel., Trudeau MC., J Neurosci. April 15, 1999; 19 (8): 2906-18.
	Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current., London B., Circ Res. November 1, 1997; 81 (5): 870-8.
	Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts., Lees-Miller JP., Circ Res. November 1, 1997; 81 (5): 719-26.
	Tissue and species distribution of mRNA for the IKr-like K+ channel, erg., Wymore RS., Circ Res. February 1, 1997; 80 (2): 261-8.
	HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine., Roy M., Circulation. August 15, 1996; 94 (4): 817-23.

???pagination.result.page??? ???pagination.result.prev??? 1 2